The last few months have been bumpy for 23andMe, with the company settling a lawsuit related to a data breach and announcing a round of layoffs, and many past customers are wondering, Can I delete ...

23andMe is in need of cash and weighing a sale of the company. The DNA-testing company said Tuesday that it is exploring strategic alternatives, including a business combination and the sale of ...

Genetic testing specialist 23andMe has launched a strategic review that could result in a sale of the company, after months of speculation about its future. The company's board has formed a ...

23andMe CEO Anne Wojcicki sounded optimistic about the company's future during an earnings call in February last year. She said the biotech company, which offers direct-to-consumer genetic testing ...

23andMe is considering a sale of the company as it weighs up strategic options, capping a torrid year for the genetic testing business. A special committee of its directors’ board is considering ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year ...

Deal Dispatch: Lovely Day To Sell Guinness? Plus, 23andMe To Rid Lineage Of Lemonaid Here's the latest M&A news and auction block updates. Among the most watched items: a TikTok deal is still in flux.

23andMe Holding Co. has launched a new polygenic risk score (PRS) report for osteoporosis, available to 23andMe+ Premium members. This report assesses an individual's genetic likelihood of ...

Genetic testing firm 23andMe (NASDAQ:ME) said it formed a special board committee to review strategic alternatives. The special committee will look at options including a sale, business ...